Neostem (NBS) Posts Q3 Loss of 6c/Share

Neostem (AMEX: NBS) reported Q3 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $3.5 million.

For earnings history and earnings-related data on Neostem (NBS) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Ascendis Pharma (ASND) Tops Q2 EPS by 132c
• BofA lifts server CPU TAM to $210bn+ on the rise of AI agents